Literature DB >> 24049429

Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.

Sharon A Huang, Janette D Lie.   

Abstract

Entities:  

Year:  2013        PMID： 24049429      PMCID： PMC3776492     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  25 in total

1.  Case report: association of combined nonarteritic anterior ischemic optic neuropathy (NAION) and obstruction of cilioretinal artery with overdose of Viagra.

Authors:  Raj Akash; Das Hrishikesh; Paul Amith; Stafanous Sabah
Journal:  J Ocul Pharmacol Ther       Date:  2005-08       Impact factor: 2.671

2.  Prevalence and risk factors for erectile dysfunction in the US.

Authors:  Elizabeth Selvin; Arthur L Burnett; Elizabeth A Platz
Journal:  Am J Med       Date:  2007-02       Impact factor: 4.965

Review 3.  Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.

Authors:  Alexander Tsertsvadze; Howard A Fink; Fatemeh Yazdi; Roderick MacDonald; Anthony J Bella; Mohammed T Ansari; Chantelle Garritty; Karla Soares-Weiser; Raymond Daniel; Margaret Sampson; Steven Fox; David Moher; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2009-11-03       Impact factor: 25.391

4.  A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.

Authors:  Irwin Goldstein; Andrew R McCullough; Leroy A Jones; Wayne J Hellstrom; Charles H Bowden; Karen Didonato; Brenda Trask; Wesley W Day
Journal:  J Sex Med       Date:  2012-01-16       Impact factor: 3.802

Review 5.  NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence.

Authors: 
Journal:  JAMA       Date:  1993-07-07       Impact factor: 56.272

Review 6.  Overview of PDEs and their regulation.

Authors:  Kenji Omori; Jun Kotera
Journal:  Circ Res       Date:  2007-02-16       Impact factor: 17.367

Review 7.  A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.

Authors:  Ferdinando Fusco; Elisa Razzoli; Ciro Imbimbo; Andrea Rossi; Paolo Verze; Vincenzo Mirone
Journal:  BJU Int       Date:  2010-06       Impact factor: 5.588

8.  Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases.

Authors:  Howard D Pomeranz; Abdhish R Bhavsar
Journal:  J Neuroophthalmol       Date:  2005-03       Impact factor: 3.042

9.  A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil.

Authors:  A Boshier; N Pambakian; S A W Shakir
Journal:  Int J Clin Pharmacol Ther       Date:  2002-09       Impact factor: 1.366

10.  Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction.

Authors:  Hyun Hwan Sung; Sung Won Lee
Journal:  Korean J Urol       Date:  2012-06-19
View more
  37 in total

1.  Canadian Urological Association guideline: Erectile dysfunction.

Authors:  Trustin Domes; Borna Tadayon Najafabadi; Matthew Roberts; Jeffrey Campbell; Ryan Flannigan; Phil Bach; Premal Patel; Gavin Langille; Yonah Krakowsky; Philippe D Violette
Journal:  Can Urol Assoc J       Date:  2021-10       Impact factor: 1.862

Review 2.  Prevalence of post-prostatectomy erectile dysfunction and a review of the recommended therapeutic modalities.

Authors:  Thiago Fernandes Negris Lima; Joshua Bitran; Fabio Stefano Frech; Ranjith Ramasamy
Journal:  Int J Impot Res       Date:  2020-11-17       Impact factor: 2.896

Review 3.  Erectile dysfunction.

Authors:  Faysal A Yafi; Lawrence Jenkins; Maarten Albersen; Giovanni Corona; Andrea M Isidori; Shari Goldfarb; Mario Maggi; Christian J Nelson; Sharon Parish; Andrea Salonia; Ronny Tan; John P Mulhall; Wayne J G Hellstrom
Journal:  Nat Rev Dis Primers       Date:  2016-02-04       Impact factor: 52.329

4.  Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.

Authors:  John P Mulhall; Ishveen Chopra; Dipen Patel; Tarek A Hassan; Wing Yu Tang
Journal:  J Sex Med       Date:  2020-03-03       Impact factor: 3.802

5.  Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.

Authors:  Mohammad Abdel-Halim; Heather Tinsley; Adam B Keeton; Mohammed Weam; Noha H Atta; Mennatallah A Hammam; Amr Hefnawy; Rolf W Hartmann; Matthias Engel; Gary A Piazza; Ashraf H Abadi
Journal:  Bioorg Chem       Date:  2020-09-28       Impact factor: 5.275

6.  Tadalafil Preserves Penile Nitric Oxide Synthase from Detrimental Effect of Paroxetine in Rats.

Authors:  Abdullah Gul; Alexander Pastuszak; Levent Kabasakal; Jenna Bates; Serdar Altinay; Duygu Sultan Celik; Atilla Semercioz; Ege Can Serefoglu
Journal:  Eurasian J Med       Date:  2019-02

7.  β-caryophyllene improves sexual performance via modulation of crucial enzymes relevant to erectile dysfunction in rats.

Authors:  Stephen A Adefegha; Ganiyu Oboh; Elijah O Olopade
Journal:  Toxicol Res       Date:  2020-08-20

8.  Treatment of Cardiovascular Dysfunction With PDE5-Inhibitors - Temperature Dependent Effects on Transport and Metabolism of cAMP and cGMP.

Authors:  Anders L Selli; Adrina K Kuzmiszyn; Natalia Smaglyukova; Timofei V Kondratiev; Ole-Martin Fuskevåg; Roy A Lyså; Aina W Ravna; Torkjel Tveita; Georg Sager; Erik S Dietrichs
Journal:  Front Physiol       Date:  2021-07-30       Impact factor: 4.566

Review 9.  A comprehensive review of urologic complications in patients with diabetes.

Authors:  Fernando Arrellano-Valdez; Marta Urrutia-Osorio; Carlos Arroyo; Elena Soto-Vega
Journal:  Springerplus       Date:  2014-09-23

10.  Investigating the Potential of Transdermal Delivery of Avanafil Using Vitamin E-TPGS Based Mixed Micelles Loaded Films.

Authors:  Abdullah A Alamoudi; Osama A A Ahmed; Khalid M El-Say
Journal:  Pharmaceutics       Date:  2021-05-17       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.